Alterity Financial Group LLC Boosts Holdings in Eli Lilly and Company (NYSE:LLY)

Alterity Financial Group LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 2.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,364 shares of the company’s stock after acquiring an additional 31 shares during the quarter. Eli Lilly and Company accounts for about 1.1% of Alterity Financial Group LLC’s holdings, making the stock its 26th biggest holding. Alterity Financial Group LLC’s holdings in Eli Lilly and Company were worth $795,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth about $3,416,206,000. Moneta Group Investment Advisors LLC lifted its position in Eli Lilly and Company by 102,752.2% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock valued at $1,992,374,000 after purchasing an additional 5,440,731 shares during the last quarter. Morgan Stanley boosted its stake in shares of Eli Lilly and Company by 44.1% during the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock valued at $4,411,740,000 after purchasing an additional 3,691,436 shares during the period. Imprint Wealth LLC grew its holdings in shares of Eli Lilly and Company by 53,716.8% in the second quarter. Imprint Wealth LLC now owns 1,751,200 shares of the company’s stock worth $175,120,000 after purchasing an additional 1,747,946 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth $445,944,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.0 %

Shares of NYSE LLY opened at $777.96 on Friday. The firm’s 50 day moving average price is $730.97 and its 200-day moving average price is $637.01. Eli Lilly and Company has a 52-week low of $334.58 and a 52-week high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The company has a market cap of $739.19 billion, a PE ratio of 134.13, a P/E/G ratio of 1.71 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.09 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 12.42 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on LLY shares. Truist Financial reissued a “buy” rating and set a $850.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 22nd. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, February 20th. Bank of America boosted their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Morgan Stanley raised their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $689.52.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 34,538 shares of the stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $631.81, for a total value of $21,821,453.78. Following the transaction, the insider now directly owns 99,719,884 shares in the company, valued at $63,004,019,910.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 195,055 shares of company stock valued at $125,254,657. 0.13% of the stock is owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.